About Aegerion
Aegerion is a company based in Cambridge (United States) founded in 2005 was acquired by Amryt Pharma in May 2019. Aegerion has raised $58.42 million across 7 funding rounds from investors including Amryt Pharma, MVM Partners and QLT. The company has 63 employees. Aegerion has completed 1 acquisition, including Myalept. Aegerion operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 63
- Stage Public
- SectorsHealthcare
- Website aegerion.com
- Social LinkedIn X
- Acquired by Amryt Pharma (May 2019)
- Legal Name Aegerion Pharmaceuticals, Inc.
- Total Equity Funding$58.42M (USD)
in 7 rounds
- Latest Funding Round$72.5M (USD), Debt – Conventional
Nov 2018
- InvestorsAmryt Pharma
& 9 more
- Employee Count63
- Investments & Acquisitions
- Acquired by
Funding Insights of Aegerion
Aegerion has successfully raised a total of $58.42M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $72.5 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58.42M
- Total Rounds 7
- Last Round Debt – Conventional — $72.5M
- First Round $22.5M
(Jun 2006)
- Investors Count 8
All 7 funding rounds of Aegerion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $72.5M | Debt – Conventional | – | – | |
| Apr 2018 | $20M | Debt – Conventional | – | – | |
| Aug 2014 | $325M | Post-IPO | – | – | – |
| Jun 2010 | $18.31M | Series B | – | – | – |
| Nov 2007 | $17.61M | Series A | – | – | – |
| Apr 2007 | $425,000 | Debt – Convertible | – | – | – |
| Jun 2006 | $22.5M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Aegerion
Aegerion has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Amryt Pharma, MVM Partners and QLT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | – | athyrium.com | New York, United States | |
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Private equity firm focused on multiple sectors | – | adventinternational.com | Sao Paulo, Brazil | |
Venture capital investments in technology startups and entrepreneurs. | – | indexventures.com | - | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
- | – | highbridge.com | - | |
Investment management firm providing capital services and financial statements. | 2012 | sarissacap.com | Greenwich, United States | |
Therapeutics for rare dermatological and orphan diseases are developed. | 2015 | amrytpharma.com | Dublin, Ireland | |
Biopharma specializing in opthalmology | 1981 | qltinc.com | Vancouver, Canada |
Investor details for Aegerion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aegerion
Aegerion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myalept.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Leptin replacement therapy is provided for generalized lipodystrophy patients. | myalept.com | – | 0 | Nov 2014 | $325M |
Complete acquisition details for Aegerion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aegerion
7 dated milestones of Aegerion across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Aegerion is founded.
- Funding First funding round of $22.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Myalept.
- Exit Acquired by QLT.
- Funding Latest funding round, Debt – Conventional, of $72.5M.
- Exit Acquired by Amryt Pharma.
Competitors of Aegerion
Aegerion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| capricor.com | 2005 | Los Angeles, United States | – | 62 | Regenerative medicine for cardiovascular disorders is developed using cell-based platforms. | |
| cardurion.com | 2017 | Boston, United States | $270M | – | Therapeutics for heart and cardiovascular diseases are developed. | |
| esperion.com | 1998 | Ann Arbor, United States | $129.7M | 240 | Therapies for lowering low-density lipoprotein cholesterol levels are developed. | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. |
Detailed competitors of Aegerion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aegerion
Websites that share an audience with Aegerion (aegerion.com).
Websites whose visitors overlap most with Aegerion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| npsp.com | 30% | – | – | View details | |
| alnylam.com | 21% | 77.8K | #414,009 | View details |
Latest news on Aegerion
Complete news archive for Aegerion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Aegerion
10 companies that operate in the same segment as Aegerion (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aegerion
Aegerion was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Aegerion is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Aegerion is a funded company, having raised a total of $58.42M across 7 funding rounds to date. The company's 1st funding round was a Series A of $22.5M, raised on Jun 2006.
Aegerion has 63 employees.
Aegerion Pharmaceuticals was established in 2005 in Cambridge, United States, within the biopharmaceutical sector. Treatments for cardiovascular and metabolic diseases are developed, including Juxtapid, which lowers low-density lipoprotein cholesterol levels, and Myalept, acquired from AstraZeneca for 325 million to address leptin deficiency complications in generalized lipodystrophy patients. Emphasis is given to solutions for hyperlipidemia assessment and management.
Aegerion's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Aegerion has made 1 acquisition, including Myalept.
Aegerion has 10 investors. Key investors include Amryt Pharma, MVM Partners, QLT, Athyrium Capital Management, and Highbridge.
Aegerion operates through Aegerion Pharmaceuticals, Inc..
Yes. Aegerion was acquired by Amryt Pharma in May 2019.